Equities research analysts at Lazard Capital Markets set a $85.00 price target on shares of Questcor Pharmaceuticals (NASDAQ:QCOR) stock in a research note issued to investors on Thursday, AnalystRatingsNetwork.com reports. The firm currently has a a “buy” rating on the stock. Lazard Capital Markets’ target price indicates a potential upside of 27.67% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Mizuho raised their price target on shares of Questcor Pharmaceuticals from $65.00 to $84.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Zacks upgraded shares of Questcor Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, August 2nd. They now have a $72.10 price target on the stock. Finally, analysts at Jefferies Group raised their EPS on shares of Questcor Pharmaceuticals in a research note to investors on Wednesday, July 31st. They now have a $65.00 price target on the stock. They previously had a $38.00 price target on the stock.
Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $63.51.
Shares of Questcor Pharmaceuticals (NASDAQ:QCOR) traded up 0.17% during mid-day trading on Thursday, hitting $66.69. 269,008 shares of the company’s stock traded hands. Questcor Pharmaceuticals has a one year low of $17.25 and a one year high of $70.55. The stock has a 50-day moving average of $53.98 and a 200-day moving average of $38.36. The company has a market cap of $3.931 billion and a price-to-earnings ratio of 17.87.
Questcor Pharmaceuticals (NASDAQ:QCOR) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $1.12 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.96 by $0.16. The company had revenue of $184.60 million for the quarter, compared to the consensus estimate of $168.96 million. During the same quarter last year, the company posted $0.65 earnings per share. Questcor Pharmaceuticals’s revenue was up 64.1% compared to the same quarter last year. Analysts expect that Questcor Pharmaceuticals will post $4.81 EPS for the current fiscal year.
In other Questcor Pharmaceuticals news, EVP David Jeffrey Medeiros sold 110,597 shares of Questcor Pharmaceuticals stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $67.85, for a total transaction of $7,504,006.45. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.